课题基金 / 基金详情

Career Development in Pediatric and Medical Oncology

Career Development in Pediatric and Medical Oncology
儿科和肿瘤内科的职业发展
批准号:
10693405
负责人:
NANCY ELLEN DAVIDSON
金额:
$56.73万
依托单位国家:
美国
项目类别:
财政年份:
1997
资助国家:
美国
项目状态:
未结题
起止时间:
1997-09-30 至 2026-08-31

项目摘要

项目成果

NANCY ELLEN DAVIDSON的其他基金

相似基金

相关文献

中文摘要
翻译
项目总结/摘要 我们正在申请儿童临床肿瘤学Paul Calabresi职业发展奖 华盛顿大学弗雷德哈钦森癌症研究中心的血液学和肿瘤学 医学院和西雅图儿童医院。职业发展计划将与我们的 儿科血液学/肿瘤学、内科肿瘤学和成人血液学培训项目 哈钦森癌症研究中心和儿科和医学系在大学 华盛顿,目标是发展和支持临床翻译研究者向 独立调查员。这个K12临床肿瘤学职业发展奖将是一个不可或缺的组成部分, 我们的计划通过支持四个独立的临床研究人员培养下一代 完成儿科或内科血液学/肿瘤学研究员培训的医生 培训计划,具有有前途的独立临床/翻译职业的跟踪记录。被带进 通过该计划,学者候选人将获得现代生物学的临床技能和基本实验室工具 并将实验室结果转化为临床应用。那些最有资格和动力进入 将选择临床转化研究的调查工作。 K12学者将获得两到三年的资助,以帮助发展必要的经验, 临床转化研究,将他们的发现转化给患者,并产生足够的数据,以帮助建立 独立的研究生涯。其项目的目的将是提供新的和有用的信息 与临床肿瘤学相关,并培养学员的临床研究能力。支持的 研究项目包括造血干细胞移植、免疫学和 免疫治疗,移植生物学,结果和生活质量研究,恶性造血,人类 免疫遗传学和实体肿瘤研究项目,包括脑肿瘤、乳腺肿瘤、卵巢肿瘤、前列腺肿瘤, 和乳房。分子生物学和基因治疗以及其他相关研究的额外项目 阿里纳斯,将可用。受训者还将获得临床方案制定、实施和 评估,并将接受生物统计学,临床试验设计和生物医学研究的教学培训 完整 该计划利用弗雷德哈钦森癌症研究的实验室和临床研究设施 中心,华盛顿大学,和西雅图儿童医院研究所,和临床 西雅图癌症护理联盟、华盛顿大学和西雅图儿童医院的设施 医院
英文摘要
PROJECT SUMMARY/ABSTRACT We are requesting funds for The Paul Calabresi Career Development Award for Clinical Oncology in Pediatric and Medical Hematology/Oncology at the Fred Hutchinson Cancer Research Center, University of Washington School of Medicine and Seattle Children’s Hospital. The Career Development Program will interface with our Pediatric Hematology/Oncology, Medical Oncology, and adult Hematology Training Programs at the Fred Hutchinson Cancer Research Center and the Departments of Pediatrics and Medicine at the University of Washington, with the goal of developing and supporting transition of clinical translational investigators into independent investigators. This K12 Career Development Award for Clinical Oncology will be an integral part of our program towards grooming the next generation of independent clinical researchers by supporting four physicians each year who have completed fellowship training in the pediatric or medical hematology/oncology training programs with track record of promising independent clinical/translational careers. Prior to entry into the program, scholar candidates will have acquired clinical skills and basic laboratory tools of modern biology and translation of laboratory findings to clinical application. Those most qualified and motivated to enter into investigative endeavors in clinical translational research will be selected. The K12 scholars will receive two to three years of funding to help develop requisite experience to conduct clinical translational research, translate their findings to patients, and generate sufficient data to help establish independent research careers. The aim of their projects will be to contribute new and useful information relevant to clinical oncology and to develop the clinical research capabilities of the trainees. The supported research projects include those in the areas of hematopoietic stem cell transplantation, immunology and immunotherapy, transplantation biology, outcome and quality of life research, malignant hematopoiesis, human immunogenetics, and programs in solid tumor research including tumors of the brain, breast, ovaries, prostate, and breast. Additional projects in molecular biology and gene therapy, as well as other relevant research arenas, will be available. Trainees will also gain experience in clinical protocol development, conduct, and evaluation, and will receive didactic training in biostatistics, clinical trial design and biomedical research integrity. This program utilizes the laboratory and clinical research facilities of the Fred Hutchinson Cancer Research Center, the University of Washington, and the Seattle Children’s Hospital Research Institute, and the clinical facilities of the Seattle Cancer Care Alliance, The University of Washington, and the Seattle Children’s Hospital.
期刊论文(43)
专著(0)
科研奖励(0)
会议论文
DOI: 10.3390/cancers14122934
发表时间: 2022-06-14
期刊: Cancers
影响因子: 5.2
作者: [Godwin CD, Rodríguez-Arbolí E, Othus M, Halpern AB, Appelbaum JS, Percival MM, Hendrie PC, Oehler VG, Keel SB, Abkowitz JL, Cooper JP, Cassaday RD, Estey EH, Walter RB]
通讯作者: Walter RB
The immunogenicity of a new human minor histocompatibility antigen results from differential antigen processing.
新的人类小型组织相容性抗原的免疫原性是由差异抗原加工引起的。
DOI: 10.1084/jem.193.2.195
发表时间: 2001-01-15
期刊: JOURNAL OF EXPERIMENTAL MEDICINE
影响因子: 15.3
作者: [Brickner, A G, Warren, E H, Caldwell, J A, Akatsuka, Y, Golovina, T N, Zarling, A L, Shabanowitz, J, Eisenlohr, L C, Hunt, D F, Engelhard, V H, Riddell, S R]
通讯作者: Riddell, S R
Quantitative, real-time polymerase chain reactions for FLT3 internal tandem duplications are highly sensitive and specific.
FLT3 内部串联重复的定量、实时聚合酶链反应具有高度敏感性和特异性。
DOI: 10.1016/s0145-2126(01)00087-x
发表时间: 2001
期刊: Leukemia research
影响因子: 2.7
作者: [Stirewalt,DL, Willman,CL, Radich,JP]
通讯作者: Radich,JP
DOI: 10.1136/jitc-2020-001591
发表时间: 2020-12
期刊: Journal for immunotherapy of cancer
影响因子: 10.9
作者: [Veatch JR, Singhi N, Jesernig B, Paulson KG, Zalevsky J, Iaccucci E, Tykodi SS, Riddell SR]
通讯作者: Riddell SR
共 13 条
    Clinical Investigator Team Leadership Award
    Continuing Umbrella Research Experiences
    Clinical Trial Reporting Program
    SENIOR LEADERSHIP
    国内基金
    海外基金
    层出镰刀菌氮代谢调控因子AreA 介导伏马菌素 FB1 生物合成的作用机理
    • 批准号:
      2021JJ40433
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2021
    • 负责人:
      孙磊
    • 依托单位:
    寄主诱导梢腐病菌AreA和CYP51基因沉默增强甘蔗抗病性机制解析
    • 批准号:
      32001603
    • 项目类别:
      青年科学基金项目
    • 资助金额:
      24.0万元
    • 批准年份:
      2020
    • 负责人:
      段真珍
    • 依托单位:
    AREA国际经济模型的移植.改进和应用
    • 批准号:
      18870435
    • 项目类别:
      面上项目
    • 资助金额:
      2.0万元
    • 批准年份:
      1988
    • 负责人:
      史树中
    • 依托单位: